A Case Report of Safe Coadministration of Amiodarone with Short‐Term Treatment Nirmatrelvir‐Ritonavir

Clinical Pharmacology & TherapeuticsVolume 113, Issue 4 p. 768-769 Letter to the Editor A Case Report of Safe Coadministration of Amiodarone with Short-Term Treatment Nirmatrelvir-Ritonavir Alice Sluijters, Alice Sluijters orcid.org/0000-0002-1412-0754 Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, Brussels, BelgiumSearch for more papers by this authorFlorian Lemaitre, Florian Lemaitre orcid.org/0000-0002-0908-3629 Louvain Center for Toxicology and Applied Pharmacology, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium Pharmacology Department, Hôpital Pontchaillou, Université Rennes, Centre Hospitalier Universitaire de Rennes, Institut National de la Santé et de la Recherche Médicale, École des Hautes Études en Santé Publique, Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR S 1085, Rennes, France Institut National de la Santé et de la Recherche Médicale, Centre d'Investigation Clinique 1414, Rennes, FranceSearch for more papers by this authorLeïla Belkhir, Leïla Belkhir Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, Brussels, Belgium Louvain Center for Toxicology and Applied Pharmacology, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, BelgiumSearch for more papers by this authorLidvine Boland, Lidvine Boland Department of Laboratory Medicine, Cliniques Universitaires Saint-Luc, Brussels, BelgiumSearch for more papers by this authorVincent Haufroid, Vincent Haufroid orcid.org/0000-0001-5040-9806 Louvain Center for Toxicology and Applied Pharmacology, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium Department of Laboratory Medicine, Cliniques Universitaires Saint-Luc, Brussels, BelgiumSearch for more papers by this authorJulien De Greef, Corresponding Author Julien De Greef [email protected] orcid.org/0000-0003-0200-1237 Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, Brussels, Belgium Louvain Center for Toxicology and Applied Pharmacology, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, BelgiumCorrespondence: Julien De Greef ([email protected])Search for more papers by this author Alice Sluijters, Alice Sluijters orcid.org/0000-0002-1412-0754 Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, Brussels, BelgiumSearch for more papers by this authorFlorian Lemaitre, Florian Lemaitre orcid.org/0000-0002-0908-3629 Louvain Center for Toxicology and Applied Pharmacology, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium Pharmacology Department, Hôpital Pontchaillou, Université Rennes, Centre Hospitalier Universitaire de Rennes, Institut National de la Santé et de la Recherche Médicale, École des Hautes Études en Santé Publique, Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR S 1085, Rennes, France Institut National de la Santé et de la Recherche Médicale, Centre d'Investigation Clinique 1414, Rennes, FranceSearch for more papers by this authorLeïla Belkhir, Leïla Belkhir Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, Brussels, Belgium Louvain Center for Toxicology and Applied Pharmacology, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, BelgiumSearch for more papers by this authorLidvine Boland, Lidvine Boland Department of Laboratory Medicine, Cliniques Universitaires Saint-Luc, Brussels, BelgiumSearch for more papers by this authorVincent Haufroid, Vincent Haufroid orcid.org/0000-0001-5040-9806 Louvain Center for Toxicology and Applied Pharmacology, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium Department of Laboratory Medicine, Cliniques Universitaires Saint-Luc, Brussels, BelgiumSearch for more papers by this authorJulien De Greef, Corresponding Author Julien De Greef [email protected] orcid.org/0000-0003-0200-1237 Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, Brussels, Belgium Louvain Center for Toxicology and Applied Pharmacology, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, BelgiumCorrespondence: Julien De Greef ([email protected])Search for more papers by this author First published: 21 December 2022 https://doi.org/10.1002/cpt.2805Citations: 2 Linked article: This article is linked to Response to “A Case Report of Safe Coadministration of Amioradone With Short-Term Treatment Nirmatrelvir-Ritonavir” by Marzolini, C. et al. Clin. Pharmacol. Ther. 113, 770 (2023). Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Marzolini, C. et al. Recommendations for the management of drug–drug interactions between the COVID-19 antiviral nirmatrelvir/ritonavir (paxlovid) and comedications. Clin. Pharmacol. Ther. 112, 1191–1200 (2022). 10.1002/cpt.2646 CASPubMedWeb of Science®Google Scholar 2Vassallo, P. & Trohman, R.G. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 298, 1312–1322 (2007). 10.1001/jama.298.11.1312 CASPubMedWeb of Science®Google Scholar 3Pollak, P.T., Bouillon, T. & Shafer, S.L. Population pharmacokinetics of long-term oral amiodarone therapy. Clin. Pharmacol. Ther. 67, 642–652 (2000). 10.1067/mcp.2000.107047 CASPubMedWeb of Science®Google Scholar 4Zhang, Y.H., Cheng, H., Alexeenko, V.A., Dempsey, C.E. & Hancox, J.C. Characterization of recombinant hERG K(+) channel inhibition by the active metabolite of amiodarone desethyl-amiodarone. J. Electrocardiol. 43, 440–448 (2010). 10.1016/j.jelectrocard.2010.04.007 CASPubMedWeb of Science®Google Scholar 5Freedman, M.D. & Somberg, J.C. Pharmacology and pharmacokinetics of amiodarone. J. Clin. Pharmacol. 31, 1061–1069 (1991). 10.1002/j.1552-4604.1991.tb03673.x CASPubMedWeb of Science®Google Scholar Citing Literature Volume113, Issue4April 2023Pages 768-769 ReferencesRelatedInformation